Wendy L. St. Peter, PharmD, FCCP, FASN, FNKF

Bio

Dr. Wendy St. Peter is a Professor in the College of Pharmacy at the University of Minnesota. Her career has been focused on improving medication management and drug safety in patients with chronic kidney disease (CKD) to improve health outcomes. She was a nephrology pharmacy clinician for 8 years as part of an interprofessional team. Dr. St. Peter conducted both clinical and retrospective research focused on impact of medication management by pharmacists on identification and resolution of medication-therapy problems as well as investigation of clinical outcomes associated with integrated pharmacy services within a large dialysis organization.

Dr. St. Peter was Associate Dean and Director, Division of Professional Education in the College of Pharmacy from 1997-2000 and is a faculty in the Social and Administrative Pharmacy graduate program. She is a co-investigator with the United States Renal Data System (USRDS) Coordinating Center (2001-2014, and 2019-2030).  She works with a team to develop the medication-focused chapters in both the end-stage renal disease (ESRD) and chronic kidney disease (CKD) sections of the USRDS Annual Data Report. She also conducts pharmacoepidemiology research using large commercial claims datasets, Medicare datasets and electronic health records.

As Director of the national Advancing Kidney Health through Optimal Medication Management (AKHOMM) initiative (https://www.kidneymedicationmanagement.org/), she is leading development of curriculum for pharmacists and other health care practitioners who care for patients with chronic kidney disease (CKD) and oversees the AKHOMM Learning and Action Collaborative (LAC). AKHOMM deployed the first LAC from July 2024-October 2025 to help implement pharmacists into nephrology as well as primary care practices to optimize medication management in patients with kidney diseases.

Dr. St. Peter has served on several national technical expert panels or external advisory boards related to drug-related effectiveness and safety in CKD patients and served on the Board of Directors of the National Kidney Initiative (a partnership between the FDA and American Society of Nephrology). She also served on the national NKF-ASN Taskforce for Reassessing the Inclusion of Race in Diagnosing Kidney Diseases and 2 international Kidney Disease Improving Global Outcomes (KDIGO) CKD Controversy Conferences and was a member of the writing committee for the 2026 AHA/ACC/ADA/ASN Cardiovascular-Kidney-Metabolic (CKM) syndrome guideline that was released in June 2026.

Dr. St. Peter has been co-leading the NKF Pharmacy Engagement workgroup since 2022 to disseminate information on eGFR for medication decision-making. This workgroup is moving into the implementation phase to help health systems implement eGFR into practice. Her current research interests include prevention and optimizing medication management in persons with CKD and CKM through pharmacist-led comprehensive medication management.

Expertise

Nephrology and Internal Medicine
Pharmacoepidemiology
Quantitative and qualitative research

Awards & Recognition

• 2025 Best Paper Award, ACCP Ambulatory Care Practice Research Network
• 2020 National Kidney Foundation, Medical Advisory Board Distinguished Service Award
• 2019 Weaver Medal for exemplary contributions to College of Pharmacy, University of MN
• 2011 Fellow of the National Kidney Foundation (FNKF)
• 2011 Finalist, Outstanding Contributions to Graduate and Professional Education Award, U of MN
• 2008 Inducted as a Distinguished Practitioner in the National Academies of Practice
• 2007 Fellow of the American Society of Nephrology (FASN)
• 2000 Teacher of the Semester and Year Awards by 3rd year Pharm.D. class (Class of 2001)
• 1996 Fellow of the American College of Clinical Pharmacy (FCCP)
• 1995 ACCP-Upjohn Pharmacoeconomics Research Award

Professional Associations

• Fellow American College of Clinical Pharmacy (ACCP) (Full member status since 1991
• Fellow since 1996) Fellow American Society of Nephrology (ASN) 2000-present)
• Fellow National Kidney Foundation
• Member Renal Physicians Association (RPA) 2023-present
• Member American Society of Health-System Pharmacists (ASHP) (through 2006, 2024-present)
• Member Minnesota Pharmacists Association
• Member American Association of Kidney Patients
• Member National Kidney Foundation Serving Minnesota
• Member National Academies of Practice in Pharmacy, Distinguished Practitioner

Selected Publications (2021-2026)

Delgado C, Baweja M, Ríos Burrows N, Crews DC, Eneanya ND, Gadegbeku CA,  Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St. Peter WL, Warfield C, Powe NR. Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report from the NKF-ASN Task Force. J Am Soc Nephrol 2021;32:1305-17. PMID: 33837122, published simultaneously in American Journal of Kidney Diseases

St. Peter WL, Aungst TD. Twenty-first century solutions to increase medication optimization and safety in kidney transplant patients (invited editorial). CJASN 2021;16:679-681. PMID: 33931416.

Hall RK, Morton S, Wilson J, Ephraim P, Boulware L, St. Peter W, Colón-Emeric C, Pendergast J, Scialla, J. Risks Associated with Continuation of Potentially Inappropriate Antihypertensive Medications in Older Adults Receiving Hemodialysis. BMC Nephrol. 2021;22, 232. PMID: 34147085

King PK, Burkhardt C, Rafferty A, Wooster J, Walkerly A, Thurber K, Took R, Masterson J, St. Peter WL, Furuno JP, Williams E, Ferren J, Rascon K. for the 2020 ACCP Transitions of Care Taskforce. Quality measures of clinical pharmacy services during transitions of care. J Am Coll Clin Pharm 2021;4:883-907. DOI: 10.1002/jac5.1479 (Top Cited article in Wiley in 2021-22).

Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA,  Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St. Peter WL, Warfield C, Powe NR. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol 2021;32(12):2994-3015. PMID: 34556489. Published simultaneously in American Journal of Kidney Diseases.

Tuttle K, Wong L, St Peter W, Roberts G, Rangaswami J, Mottl A, Kliger A, Harris R, Gee P, Fowler K, Cherney D, Brosius F, Argyropoulos C, Quaggin S. Moving from Evidence to Implementation of Breakthrough Therapies in Diabetic Kidney Disease. CJASN 2022;17(7):1092-1103 PMID: 35649722

Zhao JZ, Weinhandl ED, Carlson AM, St. Peter WL. Hypoglycemia risk with SGLT-2i or Glucagon-Like Peptide 1 receptor agonists versus sulfonylureas among Medicare insured adults with CKD in the United States. Kidney Medicine 2022;4(8):1-11. PMID: 35898692

Gray J, Hillman LA, Vivian E, St. Peter WL. Pharmacist's role in reducing medication-related racial disparities in African American patients with chronic kidney disease. JACCP 2022;5:912-20, DOI: 10.1002/jac5.1653

Zhao J, Weinhandl EW, Carlson AM, St. Peter WL. Disparities in SGLT2 inhibitor or glucagon-like peptide 1 receptor agonist initiation among Medicare insured adults with CKD in the United States. Kidney Medicine 2023;5(1):100564. doi.org/10.1016/j.xkme.2022.100564 

Kelepouris E, St. Peter WL, Neumiller J, Wright E. Optimizing multidisciplinary care of patients with chronic kidney disease and type 2 diabetes mellitus. Diabetes Therapy 2023, 14(7):1111-1136. PMID: 37209236

Hall RK, Rutledge J, Lucas A Liu CK  St Clair Russell C, St Peter W, Fish LJ, Colón-Emeric C. Stakeholder Perspectives on Factors Related to Deprescribing Potentially Inappropriate Medications in Older Adults Receiving Dialysis. Clin J Am Soc Nephrol 2023,18(10):1310-20.  PMID: 37499693.

St. Peter WL, Meaney CJ. Extending SGLT2 Inhibitor Use for People Undergoing Dialysis. (Editorial) Clin J Am Soc Nephrol 2023, 18(8):991-3. PMID: 37418254

Johansen KL, Gilbertson DT, Li S, Li S, Liu J, Roetker NS, Chertow GM, Ku E, Schulman IH, Greer RC, Chan K, Abbott KC, Butler CR, O’Hare AM, Powe NR, Reddy YNV, Snyder J, St. Peter WL, Taylor JS, Weinhandl ED, Wetmore JB. US Renal Data System 2023 Annual Data Report. Am J Kidney Dis 2024;83(4, suppl 1):A8-A13. PMID: 38519262

Neumiller JA, St. Peter WL, Schubrook JH. Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes. J Clin Med 2024;13(5):1367. PMID: 38592214

Navaneethan SD, Bansal N, Cavanaugh KL, Chang A, Crowley S, Delgado C, Estrella MM, Ghossein C, Ikizler A, Konicki H, St. Peter W, Tuttle KR, Williams J. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. American Journal of Kidney Disease 2024; Nov 18:S0272-6386(24)00977-6. PMID: 39556063.

St. Peter WL, Bzowyckyi AS, and 23 other authors.  Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions. American Journal of Health-System Pharmacy 2025;82:644-59. PMID: 39552516. (Almetrics score: 60)

Hillman L, Warfield C, St. Peter WL. Perspectives of medication-related experiences in Black persons with kidney diseases: The patient voice. American Journal of Health-System Pharmacy 2025;82(12):710-18. PMID: 40155195

Bzowyckyi AS, St. Peter WL. A call to action: Transitioning from Cockcroft-Gault estimated creatinine clearance (eCrCL) to race-free estimated glomerular filtration rate (eGFR), Editorial. JACCP 2025;8(5):324-326. https://doi.org/10.1002/jac5.70018

Nemecek B, St. Peter W, Hong L, Anderson ER, El Nekidy WS. Current Practices in Estimating Kidney Function: Insights from a Cross-Sectional Survey. JACCP 2025;8:1136-42. https://doi.org/10.1002/jac5.70123

Duru OK, Alicic R, Vadaganathn M, St. Peter W. et al. (7 other authors) A Systematic Literature Review of Coordinated Care in Cardiovascular-Kidney-Metabolic Conditions. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 2025;9(6). PMID: 41321907

Wallace JA, Rungkitwattanakul J, Khan R, Anderson L….St. Peter WL et al. (many other authors). Adopting race-free estimated glomerular filtration rate for unifying medication-related decision-making: An opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. JACCP 2025 (online ahead of print). https://doi.org/10.1002/jac5.70153

Hudson JQ, Chang AR, Condon-Martinez AJ, Maxson R, Meaney CJ, St. Peter WL. Optimizing Comprehensive Medication Management in CKD: An Opportunity to Integrate Pharmacists in the Kidney Care Team. AJKD 2025;87(3):433-42. doi: 10.1053/ j.ajkd.2025.09.024

St. Peter WL, Neumiller JJ….Tuttle KR et al. (many other authors). A Scoping Review of Pharmacist-Based Interprofessional Interventions for Management of Cardiovascular-Kidney-Metabolic Conditions. JACCP 2026;1-29. DOI: 10.1002/jac5.70123

Umaru O, Pestka DL, Sorge LA; Cheng C-H, Dryden K, Rangaswami J, Tuttle KR, Brummel A, Neumiller JJ, St. Peter WL. Gaps, Barriers and Facilitators to Implementing Comprehensive Medication Management in Cardiovascular-Kidney-Metabolic care: a Qualitative Study. JACCP (Accepted May 2026).

Ndumele CE, St. Peter WL (and 35 other authors) 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e00-e00. doi: 10.1161/CIR.0000000000001453. Published simultaneously in JACC. 
 

Grants from 2020-2026

United States Renal Data System Coordinating Center Contract: HSN 75N94024C00001, Co-I, 3/2024 to 2030.

American College of Clinical Pharmacy Foundation Award, Medication Optimization in Patients with Chronic Kidney Disease with or without Type 2 Diabetes or Heart Failure to Improve Patient-Centered Health Outcomes, Co-PI, 4/2024 to 3/2026.

NIMHD/NIH C2 DREAM Pilot Grant Program, Evaluating inequity in pharmacy access in the Twin Cities, Mentor, 7/2023 to 6/2025.

1K76AG059930-01 RO1-NIA, Medication deprescribing in geriatric patients receiving hemodialysis, Mentor, 2023 to 2025.

Office of Development and Technology, University of Minnesota grant, Reduce Medication-Related Disparities in African American Patients with Chronic Kidney Disease, PI, 8/2021 to 4/2023.

NIDDK, 1R01DK124333-01A1, Immobilized phosphate affinity material for the treatment of hyperphosphatemia, Co-I, 9/2020 to 8/2025.

United States Renal Data System Coordinating Center Contract: HSN 75N94019C00006, Co-I, 6/2019 to 6/2024.

Kidney Health Initiative, Develop Measures for Muscle Cramping in Dialysis Patients to Spur Development of Devices and Medicines for treating this Vexing Condition, Co-I, 1/2019 to 12/2020.

NIH, 1K76AG059930-01, Deprescribing for Older Dialysis Patients, Mentor, 8/2018 to 5/2023.

Analytical Research Agreement, Minneapolis Medical Research Foundation or Hennepin Healthcare Research Institute, Co-I, 2000 to present.

June 9, 2026; "First-ever guideline on cardiovascular-kidney-metabolic syndrome issued" press release (https://newsroom.heart.org/news/first-ever-guideline-on-cardiovascular-kidney-metabolic-syndrome-issued). Dr. St. Peter was on the AHA/ACC/ADA/ASN guideline writing committee.

June 1 2026; "National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Free eGFR in Medication Decision-Making" press release (https://www.kidney.org/press-room/national-kidney-foundation-and-u-s-pharmacy-organizations-call-transition-to-race-free)along with link to U.S. Pharmacy Organizations Endorsement letter (https://www.kidney.org/sites/default/files/2026-05/pharmacy_engagement_consensus_statement.pdf) was sent out on 6/1/2026. Dr. St. Peter co-led the NKF Pharmacy Leader workgroup that developed the endorsement statement and co-led the NKF Workgroup for Implementation of
Race-Free eGFR-Based Medication-Related Decisions that created the tools published on the NKF CKDIntercept website.

December 4, 2025; “Technology Drives Innovation, Accessibility When Treating Chronic Kidney Disease” AJMC Population-Health, Equities and Outcomes, American Journal of Managed Care, December, 4, 2025; Special issue no. 15. Interview with W. St. Peter (https://www.ajmc.com/view/technology-drives-innovation-accessibility-when-treating-chronic-kidney-disease)